WHWK SCHEDULE 13G/A: SEC filing

ABG Management Ltd. and affiliated reporting persons

Filed with the SEC on · accession 0001493152-26-052436

WHWK filed a SCHEDULE 13G/A (schedule 13g/a) with the SEC on Nov 16, 2026. ABG Management Ltd. and affiliated reporting persons filed an amended Schedule 13G disclosing beneficial ownership of 4,829,398 shares (7.8%) of Whitehawk Therapeutics common stock, including 3,209,926 shares issuable upon exercise of warrants. The stock moved -1.6% by the first close after the filing.

Summary of the filing

ABG Management Ltd. and affiliated reporting persons filed an amended Schedule 13G disclosing beneficial ownership of 4,829,398 shares (7.8%) of Whitehawk Therapeutics common stock, including 3,209,926 shares issuable upon exercise of warrants. Ally Bridge MedAlpha Master Fund LP no longer holds any shares.

Key details

Shares of common stock beneficially owned$4.8M
Shares of common stock held of record by ABG V-SIV Limited$1.6M
Shares issuable upon exercise of warrants held by ABG V-SIV Limited$3.2M
Total shares of common stock outstanding as of November 5, 2026$59.0M
IssuerWhitehawk Therapeutics, Inc.
Reporting personABG Management Ltd.
Reporting personAlly Bridge Group (NY) LLC
Reporting person; no longer holds sharesAlly Bridge MedAlpha Master Fund L.P.
Reporting person; general partnerABG Global Life Science Capital Partners V GP Limited
Reporting personABG Global Life Science Capital Partners V GP, L.P.
Reporting personAlly Bridge Group Global Life Science Capital Partners V, L.P.
Reporting personABG-SIV, L.P.
Reporting person; record holder of shares and warrantsABG V-SIV Limited
Controlling stockholder of abg global life science capital partners v gp limited / director of abg management ltd.Fan Yu
Director of abg global life science capital partners v gp limitedShan-ju Yeh

How WHWK stock reacted

Close before

$3.06

Nov 13, 2026

First close after

-1.63%

$3.01

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for WHWK, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for WHWK?

Click here

Frequently asked questions

What did WHWK file with the SEC on Nov 16, 2026?

WHWK filed a SCHEDULE 13G/A (SEC filing). ABG Management Ltd. and affiliated reporting persons filed an amended Schedule 13G disclosing beneficial ownership of 4,829,398 shares (7.8%) of Whitehawk Therapeutics common stock, including 3,209,926 shares issuable upon exercise of warrants. Ally Bridge MedAlpha Master Fund LP no longer holds any shares.

How do I read a SCHEDULE 13G/A?

A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G/A (schedule 13g/a): A report the company filed with the SEC (the US market regulator).

How did WHWK stock react to this filing?

WHWK closed at $3.06 before the filing and $3.01 on Nov 16, 2026 (-1.63%).

Other WHWK SEC filings

Get alerts when WHWK files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days